(GH) Guardant Health - NASDAQ
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 16.656m USD | Total Return: 167% in 12m
Avg Turnover: 274M
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 8
Warnings
Negative Equity with losses - insolvent profile
Interest Coverage Ratio -96.5 is critical
Altman Z'' -3.47 < 1.0 - financial distress zone
Choppy
Tailwinds
Rs Leader, Idiosyncratic Leader, Confidence
Guardant Health, Inc. (GH) is a precision oncology firm specializing in liquid biopsy and tissue-based molecular profiling. The company’s product portfolio includes the Guardant360 CDx for tumor mutation profiling, the Shield blood test for colorectal cancer screening, and the GuardantOMNI platform for immuno-oncology applications. These diagnostic tools utilize circulating tumor DNA (ctDNA) to detect cancer at the molecular level and provide genomic insights for therapy selection.
The company operates within the high-growth molecular diagnostics sector, where the business model relies on a combination of clinical testing volume and biopharmaceutical partnerships for companion diagnostic development. Liquid biopsies represent a significant shift in oncology, offering a non-invasive alternative to traditional surgical tissue biopsies for monitoring tumor evolution and treatment response.
Beyond diagnostics, Guardant Health provides data-driven solutions such as GuardantINFORM, which tracks longitudinal clinical outcomes to support cancer research. The company also offers the Smart Platform for multiomic analysis and GuardantConnect to match patients with relevant clinical trials based on their specific genetic alterations.
For a deeper analysis of these market dynamics and valuation metrics, consider reviewing the latest data on ValueRay. Headquartered in Palo Alto, California, Guardant Health continues to expand its reach through regulatory approvals and the integration of genomic, transcriptomic, and epigenomic data sets.
- FDA approval and Medicare reimbursement coverage for Shield colorectal cancer screening
- Biopharmaceutical partnership revenue growth from companion diagnostic and clinical trial services
- Liquid biopsy market penetration and adoption rates for Guardant360 therapy selection
- Operating margin improvement through transition toward laboratory scale and cost efficiencies
- Regulatory changes affecting Laboratory Developed Test oversight and diagnostic reimbursement rates
| Net Income: -433.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 5.08 > 1.0 |
| NWC/Revenue: 99.55% < 20% (prev 90.60%; Δ 8.95% < -1%) |
| CFO/TA -0.09 > 3% & CFO -175.4m > Net Income -433.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (131.3m) vs 12m ago 5.98% < -2% |
| Gross Margin: 64.90% > 18% (prev 61.34%; Δ 3.56% > 0.5%) |
| Asset Turnover: 66.28% > 50% (prev 57.58%; Δ 8.70% > 0%) |
| Interest Coverage Ratio: -96.55 > 6 (EBIT TTM -429.9m / Interest Expense TTM 4.45m) |
| A: 0.56 (Total Current Assets 1.37b - Total Current Liabilities 292.1m) / Total Assets 1.92b |
| B: -1.62 (Retained Earnings -3.11b / Total Assets 1.92b) |
| C: -0.26 (EBIT TTM -429.9m / Avg Total Assets 1.63b) |
| D: -0.09 (Book Value of Equity -181.1m / Total Liabilities 2.10b) |
| Altman-Z'' = -3.47 = D |
| DSRI: 0.85 (Receivables 137.4m/115.4m, Revenue 1.08b/774.0m) |
| GMI: 0.95 (GM 61.34% / 64.90%) |
| AQI: 1.16 (AQ_t 0.13 / AQ_t-1 0.11) |
| SGI: 1.40 (Revenue 1.08b / 774.0m) |
| TATA: -0.13 (NI -433.2m - CFO -175.4m) / TA 1.92b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of June 12, 2026, the stock is trading at USD 130.90 with a total of 1,472,723 shares traded.
Over the past week, the price has changed by -1.62%,
over one month by +35.35%,
over three months by +48.70% and
over the past year by +166.98%.
Guardant Health has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy GH.
- StrongBuy: 18
- Buy: 4
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 137.1 | 4.7% |
P/S = 15.419
P/B = 55.6696
Revenue TTM = 1.08b USD
EBIT TTM = -429.9m USD
EBITDA TTM = -391.0m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 1.88b USD (from shortLongTermDebtTotal, last quarter) + Leases 201.1m
Net Debt = 774.9m USD (calculated: Debt 1.88b - CCE 1.10b)
Enterprise Value = 17.4b USD (16.7b + Debt 1.88b - CCE 1.10b)
Interest Coverage Ratio = -96.55 (Ebit TTM -429.9m / Interest Expense TTM 4.45m)
EV/FCF = -65.13x (Enterprise Value 17.4b / FCF TTM -267.6m)
FCF Yield = -1.54% (FCF TTM -267.6m / Enterprise Value 17.4b)
FCF Margin = -24.77% (FCF TTM -267.6m / Revenue TTM 1.08b)
Net Margin = -40.10% (Net Income TTM -433.2m / Revenue TTM 1.08b)
Gross Margin = 64.90% ((Revenue TTM 1.08b - Cost of Revenue TTM 379.2m) / Revenue TTM)
Gross Margin QoQ = 65.22% (prev 64.63%)
Tobins Q-Ratio = 9.10 (Enterprise Value 17.4b / Total Assets 1.92b)
Interest Expense / Debt = 0.24% (Interest Expense 4.45m / Debt 1.88b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -339.6m (EBIT -429.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.72 (Total Current Assets 1.37b / Total Current Liabilities 367.2m)
Debt / Equity = -10.37 (negative equity) (Debt 1.88b / totalStockholderEquity, last quarter -181.1m)
Debt / EBITDA = -1.98 (negative EBITDA) (Net Debt 774.9m / EBITDA -391.0m)
Debt / FCF = -2.90 (negative FCF - burning cash) (Net Debt 774.9m / FCF TTM -267.6m)
Total Stockholder Equity = -235.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.58% (Net Income -433.2m / Total Assets 1.92b)
RoE = 184.3% (negative equity) (Net Income TTM -433.2m / Total Stockholder Equity -235.1m)
RoCE = -33.90% (EBIT -429.9m / Capital Employed (Equity -235.1m + L.T.Debt 1.50b))
RoIC = -21.64% (negative operating profit) (NOPAT -339.6m / Invested Capital 1.57b)
WACC = 7.68% (E(16.7b)/V(18.5b) * Re(8.53%) + D(1.88b)/V(18.5b) * Rd(0.24%) * (1-Tc(0.21)))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 4.65%
[DCF] Fair Price = unknown (Cash Flow -267.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.10 | # QB: 0
Revenue Correlation: 99.69 | Revenue CAGR: 30.80% | SUE: 2.62 | # QB: 8
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=-0.10% | Revisions=+6% | Analysts=16
EPS next Quarter (2026-09-30): EPS=-0.30 | Chg30d=+11.16% | Revisions=+41% | Analysts=16
EPS current Year (2026-12-31): EPS=-1.42 | Chg30d=+9.47% | Revisions=+56% | GrowthEPS=+22.0% | GrowthRev=+33.8%
EPS next Year (2027-12-31): EPS=-0.57 | Chg30d=+17.50% | Revisions=+11% | GrowthEPS=+59.8% | GrowthRev=+29.0%
[Analyst] Revisions Ratio: +56%